Clinical Trials on Gram-negative Bacteraemia

Total 6695 results

Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Meningococcal Infection (Healthy Volunteers)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
GlaxoSmithKline

Completed

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

Infections, Meningococcal | Meningococcal Vaccines

Germany, France
DynPort Vaccine Company LLC, A GDIT Company

Completed

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

Plague Vaccine

United States
Myanmar Oxford Clinical Research Unit
Mahidol Oxford Tropical Medicine Research Unit; Medical Action Myanmar; National... and other collaborators

Completed

Rickettsiae in Myanmar (Rickettsiae)

Rickettsiae Infections

Myanmar
Brigham and Women's Hospital
Harvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious... and other collaborators

Completed

Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts

Diarrhea | Cholera

Haiti
GlaxoSmithKline

Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Meningococcal Disease | Infections, Meningococcal

United States
PATH

Terminated

High Amylose Maize Starch for Treatment of Cholera (RESTORS)

Diarrhea

Bangladesh
DynPort Vaccine Company LLC, A GDIT Company

Completed

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

Healthy Volunteers

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

Meningitis | Meningococcal Infection

United States
Thomas Benfield

Recruiting

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV (MENPI)

Pneumococcal Infections | Hiv | Meningococcal Infections

Denmark
Johns Hopkins Bloomberg School of Public Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Animal-Assisted Visitation Program Chlorhexidine Trial

Methicillin-resistant Staphylococcus Aureus | Pseudomonas Aeruginosa | Clostridium Difficile

United States
GlaxoSmithKline

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Infections, Meningococcal

United States, Australia, Finland, Estonia, Canada, Turkey, Czechia
Novartis Vaccines

Completed

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

Meningococcal Disease

Russian Federation
Duke University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli (SHREC)

E Coli Infection

United States
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Infections, Meningococcal

United States, Puerto Rico
Matrivax Research and Development Corporation

Completed

Safety and Immunogenicity of Typhax, a Typhoid Vaccine

Typhoid Fever
Novartis Vaccines

Completed

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Meningococcal Disease

Argentina
Novartis Vaccines
GlaxoSmithKline

Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
Centre Hospitalier Universitaire de Besancon

Completed

Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings (MALDI-TRAc)

Sepsis With Escherichia Coli
Sutep Jaruratanasirikul
Prince of Songkla University

Completed

Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections

Acinetobacter Infections

Thailand
Eunice Kennedy Shriver National Institute of Child...

Completed

Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine

Typhoid Fever

United States
Zahra Vahdat Shariatpanahi

Completed

Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

Helicobacter Infection

Iran, Islamic Republic of
Novartis Vaccines

Completed

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Meningococcal Disease

United States
University of Pittsburgh

Completed

Antibiotic Resistant Community-Acquired E. Coli

E Coli Infection

United States
University of Oxford
GlaxoSmithKline; Oxford University Hospitals NHS Trust

Completed

Can we Reduce the Number of Vaccine Injections for Children? (MALTA)

Invasive Meningococcal Disease

United Kingdom
Novartis Vaccines
Novartis

Completed

Safety of MenACWY-CRM Vaccination in Adolescents

Meningococcal Disease

United States
Novartis

Completed

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Typhoid Fever

Belgium
University of Helsinki

Completed

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia (FINLEVO)

Sepsis | Bacteremia | Staphylococcus Aureus | Endocarditis

Finland
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
Mahidol University

Recruiting

Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection

Acinetobacter Infections

Thailand
GlaxoSmithKline
Bill and Melinda Gates Foundation; Wellcome Trust; Biomedical Advanced Research... and other collaborators

Recruiting

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

Salmonella Infections

Belgium, Malawi
Johns Hopkins Bloomberg School of Public Health
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7)

Diarrhea | Cholera | Stunting
EuBiologics Co.,Ltd

Completed

Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Typhoid Fever

Philippines
UCSF Benioff Children's Hospital Oakland
Gilead Sciences

Terminated

The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas (A-PACT)

Tracheostomy Infection

United States
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
DongGuk University

Completed

Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

Acinetobacter Infections

Korea, Republic of
Novartis Vaccines

Completed

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Meningococcal Disease

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Meningococcal Disease

Italy, Poland, Russian Federation, Spain, United Kingdom
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Safety Surveillance of MenACWY-CRM Vaccine in Children

Meningococcal Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

CVD 909 Vi Prime Boost Study

Typhoid Fever

United States
Novartis

Completed

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Typhoid Fever

Belgium
Novartis

Completed

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Typhoid Fever

Belgium
Dallas VA Medical Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Unknown

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Helicobacter Infection

United States

3

Subscribe